Long acting injectable hormonal contraceptives.
Injectable hormonal preparations can be highly effective and satisfactory contraceptives. The two main preparations available today are depot medroxy progesterone acetate (DMPA) and norethisterone oenanthate (NET-OEN), but several other approaches are currently under clinical trial. Injectable contraceptives have some unique advantages which give them justifiably wide appeal amongst many groups of women. However, they do have a number of disadvantages including invariable menstrual disturbance and a delay in the return of fertility. One formulation of DMPA, Depo-Provera, is probably the most extensively investigated single hormonal contraceptive ever made. These studies indicate that it is remarkably safe and does not face any more unresolved issues than the combined pill, intrauterine device or tubal sterilization. However, for a number of disparate emotional and political reasons it has attracted the attention of several consumer and feminist groups, who have waged a prolonged and quite unjustified campaign against it. It is to be hoped that future debate will be conducted on a more informed, rational and less emotional basis. Injectable contraceptives should have an important place in the family planning armamentarium of all countries, and current developments should lead to a decrease in concerns about presently available agents. This should further increase the widespread acceptability of this approach to contraception.
D000818:Animals; D001943:Breast Neoplasms / Q000139:chemically induced; D003270:Contraceptive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004285:Dogs; D004334:Drug Administration Schedule; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D007247:Infertility, Female / Q000139:chemically induced; D007263:Infusions, Parenteral; D007774:Lactation / Q000187:drug effects; D008253:Macaca mulatta; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017258:Medroxyprogesterone Acetate; D008598:Menstruation / Q000187:drug effects; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077563:Norethindrone Acetate; D011247:Pregnancy; D013997:Time Factors; D014594:Uterine Neoplasms / Q000139:chemically induced
D003270:Contraceptive Agents; D003692:Delayed-Action Preparations; D000077563:Norethindrone Acetate; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D009640:Norethindrone